[Intravesical therapy: Influence on superficial bladder cancer progression].
OBJECTIVE
To review the influence of various intravesical treatments on superficial bladder cancer progression.


METHODS
We retrospectively reviewed 473 superficial bladder neoplasias. Based on diagnosis and transurethral resection of bladder tumor (TUR BT), and depending on pathology, we proposed different treatment and follow-up schemes, with BCG in 139 cases and intravesical chemotherapy, mainly Mytomicin C, in 80.


RESULTS
Overall, the use or not of bladder instillations did not show statistically significant differences in time to progression. The use of intravesical therapy and maintenance therapy was an independent risk factor for disease-free time to progression when compared with induction.


CONCLUSIONS
The use of maintenance intravesical therapy with BCG resulted in a delayed progression of superficial bladder cancer, so that it seems the most effective treatment, mainly in moderate-high risk tumors.
García Rodríguez
Jorge
J
Servicio de Urología I, Hospital Central de Asturias, Oviedo, Asturias, España. jgrmed@hotmail.com
Fernández Gómez
Jesús María
JM
Escaf Barmadah
Safwan
S
Alvarez Múgica
Miguel
M
Rodríguez Robles
Laura
L
Martín Benito
José Luis
JL
San Martín Blanco
Alfonso
A
Regadera Sejas
Javier
J
D000276:Adjuvants, Immunologic / Q000008:administration & dosage*; D000283:Administration, Intravesical; D000970:Antineoplastic Agents / Q000008:administration & dosage*; D001500:BCG Vaccine / Q000008:administration & dosage*; D018450:Disease Progression; D006801:Humans; D016685:Mitomycin / Q000008:administration & dosage*; D012189:Retrospective Studies; D001749:Urinary Bladder Neoplasms / Q000188:drug therapy* / Q000473:pathology*
D000276:Adjuvants, Immunologic; D000970:Antineoplastic Agents; D001500:BCG Vaccine; D016685:Mitomycin